IRIS International's NADiA ProsVue Prognostic Prostate Cancer Test Data From Multi-Center Clinical Study

IRIS International, Inc. IRIS, announced today that a poster of the results of a multi-center clinical study utilizing its proprietary NADiA ProsVue prognostic prostate cancer test in 304 post-radical prostatectomy patients, was presented last week at the American Urological Association 2011 Annual Meeting in Washington, DC by principal study investigator and lead author, Judd W. Moul, MD, Director of the Prostate Cancer Center and the Division Chief of Urology at Duke University Medical Center. The Company also announced the submission of an accelerated sample stability study requested by the FDA as part of IRIS's reply to an "Additional Information" letter received from the FDA in March 2011.